Vifor Pharma settles CMA investigation pledging to rectify potentially misleading messages about Monofer.

Article summary

The Competition and Markets Authority (CMA) has accepted final commitments from Vifor Pharma on 23 May 2025, addressing concerns about its abuse of dominance in the supply of intravenous (IV) iron deficiency treatments for NHS patients in the UK. Vifor has committed to making a payment of £23 million to healthcare systems across the four nations, following concerns that its claims could have had an adverse financial impact on the NHS. It has also agreed to write to healthcare providers to correct any potentially misleading communications regarding the safety of competing product Monofer, produced by Pharmacosmos, and its own product Ferinject. In addition, Vifor will introduce several measures to prevent the dissemination of misleading information in the future.